






# t:slim X2

WITH **Control-IQ** TECHNOLOGY

Control-IQ™ advanced hybrid closed-loop technology on the t:slim X2™ insulin pump predicts and helps reduce highs and lows to help increase time in range.\*

## HOW CONTROL-IQ TECHNOLOGY WORKS

The t:slim X2 insulin pump with Control-IQ technology is designed to help increase time in range (3.9-10.0 mmol/L)\* using Dexcom G6 continuous glucose monitoring (CGM) values to predict glucose levels 30 minutes ahead and adjust insulin delivery accordingly; including delivery of automatic correction boluses† (up to one per hour).

10.0		Delivers an automatic correction bolus if sensor glucose is predicted to be above 10 mmol/L
8.9		Increases basal insulin delivery if sensor glucose is predicted to be above 8.9 mmol/L
6.25		Maintains active Personal Profile settings
3.9		Decreases basal insulin delivery if sensor glucose is predicted to be below 6.25 mmol/L
mmol/L		Stops basal insulin delivery if sensor glucose is predicted to be below 3.9 mmol/L

\*As measured by CGM




*Stacy*  
diagnosed 2006

## CLINICAL STUDY RESULTS



More  
time in  
range\*

Average additional time in range per day for study participants who used Control-IQ technology.<sup>1</sup>



Said  
it's easy  
to use

Percent of study participants who used Control-IQ technology and said it was easy to use.<sup>2</sup>



The t:slim X2 insulin pump has a sleek design matched with powerful features you would expect in a modern device.

Isaiah  
diagnosed 2010



Remote Software  
Updates<sup>†</sup>



Rechargeable  
Battery



Watertight  
Construction<sup>§</sup>

## Zero Fingersticks

Dexcom G6 CGM integration with the t:slim X2 pump provides exceptional accuracy<sup>3</sup> for optimised insulin delivery. Dexcom G6 requires zero fingersticks for calibration or mealtime dosing.<sup>^</sup>



Dexcom G6 CGM system shown at actual size. ^ If glucose alerts and Dexcom G6 CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.



Responsible Use  
of Control-IQ  
Technology

Control-IQ technology does not prevent all high and low blood glucose events, and is not a substitute for meal boluses and active self-management of your diabetes. Control-IQ technology will not be able to predict sensor glucose values and adjust insulin dosing if your CGM is not working properly or is unable to communicate with your pump. Always pay attention to your symptoms and blood glucose levels and treat accordingly.

**Air Liquide**  
HEALTHCARE

t:simulator App  
A free virtual pump demo



**TANDEM**  
DIABETES CARE

\*As measured by CGM. † If glucose values are predicted to be above 10.0 mmol/L, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 6.1 mmol/L and delivers 60% of that value. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled. ‡ Additional feature updates are not currently available for the t:slim X2 insulin pump with Control-IQ technology and are subject to regulatory approvals. Future updates for some or all of Tandem's products may not be developed and may not be offered everywhere. Software updates are only available to customers who are in warranty at the time they update their pump, and may require a prescription and additional training. Charges may apply. Tandem may discontinue select software and features over time at its discretion. § Tested to a depth of 0.91 meters for 30 minutes (IPX7). References: 1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomised, multicenter trial of closed-loop control in type 1 diabetes. *N Eng J Med*. 2019;381(18):1701-1717. 2. Brown, S. Clinical acceptance of the artificial pancreas: Glycemia outcomes from a 6-month multicenter RCT. 2019 ADA 79th Scientific Sessions, San Francisco, CA. 3. Dexcom G6 CGM System User Guide, 2018.

**Important Safety Information:** The t:slim X2 insulin pump and the t:slim X2 insulin pump with Control-IQ technology are intended for single patient use. The t:slim X2 pump and the t:slim X2 pump with Control-IQ technology are indicated for use with NovoRapid or Humalog U-100 insulin. **t:slim X2 insulin pump:** The t:slim X2 pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices. The t:slim X2 pump is indicated for use in individuals six years of age and greater. **t:slim X2 insulin pump with Control-IQ technology:** The t:slim X2 pump with Control-IQ technology is intended for use with a compatible continuous glucose monitor (CGM, sold separately) and the t:slim X2 pump to automatically increase, decrease, and suspend delivery of basal insulin based on CGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The t:slim X2 pump with Control-IQ technology is intended for persons six years of age and greater.

**WARNING:** The t:slim X2 pump with Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 25 kilograms.

The t:slim X2 pump with Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use the t:slim X2 pump with Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and the t:slim X2 pump with Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognise all functions of the pump, including alerts, alarms, and reminders. All Tandem Diabetes Care pumps, transmitters, and sensors must be removed before MRI, CT, or diathermy treatment. Visit [tandemdiabetes.com/safetyinfo](https://tandemdiabetes.com/safetyinfo) for additional important safety information.

© 2020 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, t:simulator, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. Dexcom and Dexcom G6 are either trademarks or registered trademarks of Dexcom, Inc. in the United States and/or other countries. Apple and the Apple logo are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC. All other third-party marks are the property of their respective owners. ML-1006754\_A

For further information please contact us:  
[www.airliquidehealthcare.co.uk/diabetes-service](https://www.airliquidehealthcare.co.uk/diabetes-service)  
t: 0800 012 1560 e: [diabetes.info@airliquide.com](mailto:diabetes.info@airliquide.com)

Air Liquide Healthcare is a world leader in medical gases, home healthcare, hygiene products and healthcare specialty ingredients. It aims to provide customers in the continuum of care from hospital to home with medical products, specialty ingredients and services that contribute to protecting vulnerable lives.

D5019200 - 09/2020